Capítulo 1967: Chapter 1341: The Patient’s Iron Fist
On a rainy night in New York, the study room of Old Walker’s mansion was brightly lit.
The curtains were tightly drawn, and twelve people sat around a heavy mahogany table. There were no assistants, no recording devices, only a glass of water or coffee in front of each person, and an almost palpable seriousness in the air.
“Everyone is here.” Old Walker sat at the head of the table, his voice calm. “Everyone present has received the sa notice and faces the sa predicant. Ti is of the essence, so let’s get straight to the topic: how to bring back K Therapy and ensure it is never taken away again.”
Sitting to his left was Mark Reynolds, the founder of a social dia empire, in his early forties, lightly tapping the table. “My people have analyzed all public data and internal sources. The core driving this restriction is the ‘Traditional dicine Interest Protection Alliance,’ a shadow lobbying network led by Horton and funded by seven pharmaceutical companies. They’ve spent four months weaving a net within the FDA, NIH, and key congressional committees.”
He brought up a relational diagram on his tablet, projecting it onto the wall. Intricate lines connected nas, institutions, political action committees, and the flow of funds.
“Their argunt is to ‘protect patients from the risks of unverified therapies,'” Reynolds sneered, “but the data doesn’t lie. In the past five years, these seven pharmaceutical companies’ patents in the tumor field have successively expired, and revenue expectations have dropped by 37%. System regulation theory will gradually replace these traditional therapies in the future. This isn’t a safety issue, it’s a survival issue.”
“So they’re afraid,” said Alex Carter, the AI giant founder. Leaning back in his chair, his treatnt-thinned hair made him look older than his actual age, but his mind remained sharp. “Afraid of a new technology that doesn’t require their expensive targeted drugs.”
“It’s more than just fear,” Senator Richard Watson spoke slowly, a veteran politician on the Energy and Comrce Committee. “They are portraying system dicine as dangerous and uncontrollable, and this concept is being repeatedly echoed by certain dia.”
Lillian Windsor joined via video from London, her image on the corner of the screen with a backdrop of a classical English study. “The situation in the United Kingdom is similar but more covert. Our dicine and Health Products Regulatory Agency has received an evaluation report from an expert group questioning the long-term safety of system regulation therapies. But as far as I know, three mbers of this expert group have undisclosed consultancy contracts with certain pharmaceutical giants. In fact, when K Therapy was going global, they tried this, though they failed. This ti it’s a well-prepared coback. They want to solve both system regulation theory and K Therapy at once.”
“Australia, Canada, Japan… the sa pattern,” Walker concluded. “This is a multinational coordinated action. So our response must also be internationally coordinated.”
He looked around the room: “We all rely on K Therapy to survive, or at least see the hope of living on. Anyone who wants to strike against K Therapy and system regulation theory is threatening our very lives!”
“What exactly are we going to do?” asked Colbert, the hedge fund magnate, his fingers unintentionally tapping the table, a habitual action when pondering market fluctuations. “Short their stock? I could evaporate twenty percent of the seven companies’ market value within a week. For my life, I would do anything.”
Reynolds said, “Public opinion is key. My platform can tweak the algorithm to give voices supporting Professor Yang’s theory a hundredfold exposure. Simultaneously, we can precisely push negative news about those pharmaceutical companies – clinical trial failures, side effect scandals, investigations into high pricing.”
Carter added: “My AI team can analyze all related regulatory docunts to identify procedural loopholes and conflicts of interest. For instance, during the creation of that FDA ‘New Guidelines for Combination Therapies,’ there were four violations of the Federal Advisory Committee Act’s transparency requirents.”
Senator Watson flashed a politician’s smile: “Congressional hearings are a great stage. I can convene the heads of the FDA and NIH, along with these pharmaceutical CEOs, and ask a few straightforward questions in front of the caras. For example, why reject a Nobel Prize-winning theory? Is it because they can’t patent it? Which is more important, patient lives or company profits?”
Lady Windsor nodded elegantly: “There’s a similar chanism in the Upper House. Moreover, the health concerns of royal family mbers always garner special dia attention.”
“There’s also the legal avenue,” said a lawyer speaking in a low voice, representing a family mber of a Supre Court judge but not revealing his na. “If we can prove these restrictions are based on misinformation or conflicts of interest, we can initiate a class-action lawsuit accusing the regulatory agencies of ‘arbitrariness and caprice,’ violating the Administrative Procedure Act. Our chances aren’t slim.”
Walker listened quietly, waiting for everyone to speak before he began:
“All these actions must be launched simultaneously. Next Monday morning at nine a.m., New York, London, Washington, Tokyo, Sydney… simultaneous execution. Before the stock market opens, Colbert’s short report is released; at 9:05, Reynolds’ platform pushes the top-story feature; at 9:30, Senator Watson’s hearing subpoenas are issued; at 10:00, Lady Windsor raises an urgent inquiry in the UK’s Upper House… we will create a perfect storm, giving them no chance to breathe.”
He paused, his gaze sharp:
“But our target is not to destroy these companies, but to force them to change their stance: to resu cooperation with Yang Ping’s team, to acknowledge the scientific status of system regulation theory, to establish a fair regulatory frawork. That is our only demand.”
User Comments
0 comments from readers